Brief Article
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Radiol. Mar 28, 2014; 6(3): 48-55
Published online Mar 28, 2014. doi: 10.4329/wjr.v6.i3.48
Cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography in tumours other than lung cancer: A systematic review
Salvatore Annunziata, Carmelo Caldarella, Giorgio Treglia
Salvatore Annunziata, Carmelo Caldarella, Institute of Nuclear Medicine, Catholic University of the Sacred Heart, 00168 Rome, Italy
Giorgio Treglia, Department of Nuclear Medicine and PET/CT Center, Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland
Author contributions: All authors contributed to the manuscript.
Correspondence to: Salvatore Annunziata, MD, Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Largo Gemelli 8, 00168 Rome, Italy. salvatoreannunziata@live.it
Telephone: +39-63-0154978 Fax: +39-63-013745
Received: November 2, 2013
Revised: December 31, 2013
Accepted: February 16, 2014
Published online: March 28, 2014
Core Tip

Core tip: Evidence based data about the cost-effectiveness of Fluorine-18-Fluorodeoxyglucose positron emission tomography (FDG-PET) or PET/computed tomography (PET/CT) in lung cancer already exist. The aim of our study is to systematically review published data on the cost-effectiveness of FDG-PET or PET/CT in tumours other than lung cancer.